Compare DexCom, Inc. (DXCM) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hyatt Hotels Corporation — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while Hyatt Hotels Corporation trades at $186.9 (market cap $17.98B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | H | |
|---|---|---|
Market Cap | $28.06B | $17.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $202.09 |
52-Week Low | $54.84 | $135.01 |
Enterprise Value | $27.03B | $21.83B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Hyatt Hotels (H) trades at $190.07, up 0.2% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $198.20. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025, while revenue grew to $7.10B in 2025. The company announced new hotel developments, including the Hyatt Regency Tucson, signaling expansion efforts.
The outlook is cautiously optimistic, supported by analyst buy ratings and strategic growth, but risks include negative net income margins, high debt levels, and macroeconomic sensitivity. Investors should weigh solid revenue trends against profitability challenges and monitor upcoming Q2 2026 earnings for confirmation of recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
